Skip To Main Content
Este sitio web está dirigido exclusivamente a profesionales de la salud en Colombia, Perú, Ecuador, Pacífico y el Caribe
Campus
Campus
View Full Results

Actualización normativa

En un entorno en constante cambio como el sistema de salud, es fundamental mantenerse al día con las nuevas normativas que afectan tanto a profesionales como a pacientes. En este espacio encontrará las leyes, decretos, resoluciones y acuerdos relacionados con el sistema de salud dinámico y en evolución.

También encontrará resúmenes, análisis y todo lo relacionado con la más reciente normatividad, para comprender el posible impacto de los cambios hacia los diferentes actores del sistema.

Ordenar por
The VESTIGE trial

The VESTIGE trial

Evaluating the effect of dupilumab on type 2 airway inflammation and mucus plugging in patients with uncontrolled moderate-to-severe asthma.1

Ver más
Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.1 The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3,4

Ver más
Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.1 The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3,4

Ver más
Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.1 The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3,4

Ver más
Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.1 The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3,4

Ver más
Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.1 The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3,4

Ver más
IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP

IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP

Ver más
IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP

IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP

Ver más
IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP

IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP

Ver más
IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP

IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP

Ver más
IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP

IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP

Ver más
IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP

IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP

Ver más

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

 

MAT-CO-2400825 V1.0 03/2024